In vitro inhibition of CYP2C8, CYP2C9, CYP2C19, and CYP2B6
In vitro CYP3A4 induction
In vitro inhibition of UGT isoforms and drug transporters
“Lanifibranor directly inhibited UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A9, UGT2B7, UGT2B15 and UGT2B17 with IC50 values of 13, 26 to 38, 20, 83, 42, 33, 23 and 22 μM, respectively.” (opens the source at this quote in a new tab)
“Lanifibranor was shown to inhibit uptake and efflux transporters but with relatively high IC50 values: MDR1 (8.5 μM), BCRP (15.2 μM), BSEP (16.8 μM), OCT2 (267 μM), except for OATP1B1/3 (~1 µM).” (opens the source at this quote in a new tab)
Simvastatin: clinical interaction study S337.1.002
CYP2B6 and CYP2C8 substrates: excluded by protocol amendment
Empagliflozin: combination assessed for interaction on glycemic control